OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer
Rona Yaeger, Nataliya V. Uboha, Meredith S. Pelster, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 982-993
Open Access | Times Cited: 28
Rona Yaeger, Nataliya V. Uboha, Meredith S. Pelster, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 982-993
Open Access | Times Cited: 28
Showing 1-25 of 28 citing articles:
Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance
Venu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.
Nature Cancer (2024) Vol. 5, Iss. 9, pp. 1352-1370
Open Access | Times Cited: 9
Venu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.
Nature Cancer (2024) Vol. 5, Iss. 9, pp. 1352-1370
Open Access | Times Cited: 9
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
Yuankai Shi, Jian Fang, Ligang Xing, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 1
Yuankai Shi, Jian Fang, Ligang Xing, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 1
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
Jakob M. Riedl, Ferran Fece de la Cruz, W. Marston Linehan, et al.
Annals of Oncology (2025)
Open Access | Times Cited: 1
Jakob M. Riedl, Ferran Fece de la Cruz, W. Marston Linehan, et al.
Annals of Oncology (2025)
Open Access | Times Cited: 1
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Primary Urethral Adenocarcinoma Harbors Recurrent Kras and Egfr Alterations
Ting Zhao, A. John Iafrate, Chin‐Lee Wu
(2025)
Closed Access
Ting Zhao, A. John Iafrate, Chin‐Lee Wu
(2025)
Closed Access
Therapiekonzepte sowie Prävention/Überwindung von Resistenzen
Alexander Kretzschmar
Onkologische Welt (2025) Vol. 16, Iss. 01, pp. 6-7
Closed Access
Alexander Kretzschmar
Onkologische Welt (2025) Vol. 16, Iss. 01, pp. 6-7
Closed Access
Efficacy and safety of KRAS -G12C inhibitors in colorectal cancer: a systematic review of clinical trials
Mohamed Saad Sayed, Yassine Alami Idrissi, Owais Ahmed, et al.
Medical Oncology (2025) Vol. 42, Iss. 4
Closed Access
Mohamed Saad Sayed, Yassine Alami Idrissi, Owais Ahmed, et al.
Medical Oncology (2025) Vol. 42, Iss. 4
Closed Access
Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
Ramesh R. Kale, Charudatt Samant, Krishnadas Nandakumar, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151688-151688
Closed Access
Ramesh R. Kale, Charudatt Samant, Krishnadas Nandakumar, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151688-151688
Closed Access
Primary Urethral Adenocarcinoma Harbors Recurrent KRAS and EGFR Alterations
Ting Zhao, A. John Iafrate, Chin‐Lee Wu
Human Pathology (2025) Vol. 157, pp. 105771-105771
Closed Access
Ting Zhao, A. John Iafrate, Chin‐Lee Wu
Human Pathology (2025) Vol. 157, pp. 105771-105771
Closed Access
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer
Filippo Pietrantonio, Lisa Salvatore, Taito Esaki, et al.
Journal of Clinical Oncology (2025)
Closed Access
Filippo Pietrantonio, Lisa Salvatore, Taito Esaki, et al.
Journal of Clinical Oncology (2025)
Closed Access
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms
Xiaojuan Yang, Hong Wu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Xiaojuan Yang, Hong Wu
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
The Current Role of Circulating Tumor DNA in the Management of Pancreatic Cancer
M.C. Cox, Dominic Vitello, Akhil Chawla
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access
M.C. Cox, Dominic Vitello, Akhil Chawla
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access
Adaptive Plasticity Tumor Cells Modulate MAPK-Targeting Therapy Response in Colorectal Cancer
Oscar E. Villarreal, Yixin Xu, Ha Tran, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Oscar E. Villarreal, Yixin Xu, Ha Tran, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Predicting immunotherapy prognosis and targeted therapy sensitivity of colon cancer based on a CAF-related molecular signature
Leqian Ying, Lu Zhang, Yanping Chen, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Leqian Ying, Lu Zhang, Yanping Chen, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
What Is Next for Refractory Colorectal Cancer CRC? Looking Beyond SUNLIGHT, FRESCO2, RECURSE and CORRECT
Sara Cherri, Michela Libertini, Silvia Noventa, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2522-2522
Open Access
Sara Cherri, Michela Libertini, Silvia Noventa, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2522-2522
Open Access
CBX2 as a therapeutic target in colorectal cancer: insights into the altered chromatin accessibility via RUNX1-CBX2-MAP4K1 axis
Bangting Wang, Shijie Zhang, Yumeng Guo, et al.
Oncogene (2025)
Closed Access
Bangting Wang, Shijie Zhang, Yumeng Guo, et al.
Oncogene (2025)
Closed Access
Endothelial cell in tumor angiogenesis: Origins, mechanisms, and therapeutic implication
Yulong Han, B Q Zhu, Shu Meng
Genes & Diseases (2025), pp. 101611-101611
Open Access
Yulong Han, B Q Zhu, Shu Meng
Genes & Diseases (2025), pp. 101611-101611
Open Access
Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review
Fan Zhang, Banglu Wang, Menghuan Wu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Fan Zhang, Banglu Wang, Menghuan Wu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial
Daniel H. Ahn, Maya Ridinger, Timothy Lewis Cannon, et al.
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 3
Daniel H. Ahn, Maya Ridinger, Timothy Lewis Cannon, et al.
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 3
Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer
Jeffrey H. Becker, Anastasia E. Metropulos, Christina Spaulding, et al.
Cancer Research (2024) Vol. 84, Iss. 21, pp. 3629-3639
Open Access | Times Cited: 2
Jeffrey H. Becker, Anastasia E. Metropulos, Christina Spaulding, et al.
Cancer Research (2024) Vol. 84, Iss. 21, pp. 3629-3639
Open Access | Times Cited: 2
Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer
Hirotaka Miyashita, David S. Hong
Journal of Cancer Immunology (2024) Vol. 6, Iss. 2, pp. 62-69
Open Access | Times Cited: 1
Hirotaka Miyashita, David S. Hong
Journal of Cancer Immunology (2024) Vol. 6, Iss. 2, pp. 62-69
Open Access | Times Cited: 1
KRAS, a New Target for Precision Medicine in Colorectal Cancer?
Alice Boilève, Cristina Smolenschi, Aurélien Lambert, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3455-3455
Open Access | Times Cited: 1
Alice Boilève, Cristina Smolenschi, Aurélien Lambert, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3455-3455
Open Access | Times Cited: 1
Origin, development and therapy of colorectal cancer from the perspective of a biologist and an oncologist
Jiří Švec, Jakub Onhajzer, Vladimír Kořínek
Critical Reviews in Oncology/Hematology (2024) Vol. 204, pp. 104544-104544
Open Access | Times Cited: 1
Jiří Švec, Jakub Onhajzer, Vladimír Kořínek
Critical Reviews in Oncology/Hematology (2024) Vol. 204, pp. 104544-104544
Open Access | Times Cited: 1
Therapeutic Advances in Gastrointestinal Cancers: Immuno-oncology and Beyond
Saba Jalali
EMJ Oncology (2024), pp. 57-68
Open Access
Saba Jalali
EMJ Oncology (2024), pp. 57-68
Open Access
